EU regulators have approved Pfizer (NYSE:PFE) and AbbVie’s (NYSE:ABBV) antibiotic product Emblaveo for the treatment of serious infections due to multi-drug resistant Gram-negative bacteria. Pfizer ...

EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be approved by the FDA for complicated intra-abdominal infections with limited ...

Approval of this indication is based on limited clinical safety and efficacy data for Emblaveo. In REVISIT, study participants with cIAI (n=312) were randomly assigned 2:1 to receive ...

AbbVie's combination antibiotic Emblaveo has gotten federal approval to treat complicated intra-abdominal infections, making it the first and only such therapy approved to fight antimicrobial ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The EU has approved a new antibiotic for serious illnesses such as pneumonia and urinary tract infections, ...

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

Feb 7 (Reuters) - AbbVie (ABBV.N), opens new tab said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections, including those caused by ...

NORTH CHICAGO, Ill., Feb. 7, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam), as the first and only ...

Please provide your email address to receive an email when new articles are posted on . Emblaveo is the first monobactam/beta-lactamase inhibitor and antibiotic combination approved for this condition ...

The Food and Drug Administration (FDA) has approved Emblaveo™ (aztreonam and avibactam), in combination with metronidazole, for patients 18 years and older who have limited or no alternative options ...

"The continued evolution of antimicrobial resistance among Gram-negative bacteria has left some patients with little to no treatment options, resulting in extended hospital stays, additional morbidity ...